Takeda appoints David Henderson as Franchise Director, Specialty for Oceania

October 25, 2025

Takeda today announced the appointment of David Henderson as Franchise Director, Specialty for Oceania, effective 10 November 2025.

Mr Henderson joins Takeda with more than 20 years of experience in the biopharmaceutical sector, having held senior leadership roles across Australia, New Zealand, the United States, and Europe. He most recently served as Managing Director for Australia and New Zealand at Biogen, with responsibility for commercial operations and strategy across multiple therapy areas, including multiple sclerosis (MS) and spinal muscular atrophy (SMA).

His prior roles have encompassed biosimilars, neuroscience, rare diseases, and early asset planning, including extensive cross-functional management and commercial execution in regulated markets.

Mr Henderson said:

“I am delighted to be joining Takeda and look forward to working with such a talented and dedicated team. What stands out most about Takeda is its talented and purpose-driven people, whose commitment to patients and one another has underpinned the organisation’s strong performance.

I am excited to contribute and support the culture of innovation and collaboration as Takeda’s portfolio of therapies continues to evolve to meet the needs of patients across Australia and New Zealand.”

Takeda Oceania General Manager Dave Pearce said:

“We are pleased to welcome David at a time when Takeda is preparing to launch new therapies from a strong late-stage pipeline. His experience in specialty medicines and ability to navigate complex market environments will be instrumental as we continue to expand access and deliver for patients and partners across the region.”

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com,

Media Contact:

Takeda Oceania Communications

[email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda today announced the appointment of David Henderson as Franchise Director, Specialty for Oceania, effective 10 November 2025. Mr Henderson joins Takeda with more than 20 years of experience in the biopharmaceutical sector, having held senior leadership roles across Australia, New Zealand, the United States, and Europe. He most recently served as Managing Director for Australia and New Zealand at Biogen, with responsibility for commercial operations and strategy across multiple therapy areas, including multiple sclerosis (MS) and spinal muscular atrophy (SMA). His prior roles have encompassed biosimilars, neuroscience, rare diseases, and early asset planning, including extensive cross-functional management and commercial execution in regulated markets. Mr Henderson said: “I am delighted to be joining Takeda and look forward to working with such a talented and dedicated team. What stands out most about Takeda is its talented and purpose-driven people, whose commitment to patients and one another has underpinned the organisation’s strong performance. I am excited to contribute and support the culture of innovation and collaboration as Takeda’s portfolio of therapies continues to evolve to meet the needs of patients across Australia and New Zealand.” Takeda Oceania General Manager Dave Pearce said: “We are pleased to welcome David at a time when Takeda is preparing to launch new therapies from a strong late-stage pipeline. His experience in specialty medicines and ability to navigate complex market environments will be instrumental as we continue to expand access and deliver for patients and partners across the region.” ## About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](https://takeda.com/), ### Media Contact: Takeda Oceania Communications [[email protected]](mailto:[email protected]) ## Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.